Events

Apollo Therapeutics is delighted to announce that Rachel Gurrell PhD, VP, Global Program Lead, and Matthew Cardinal, Senior Director, Clinical Science, will be attending PVRI 2026 which is taking place from January 28 to February 1, 2026 in Dublin, Ireland.  
 
The team will present a poster on a phase 1 trial of APL-9796 in healthy adults on Saturday, January 31, from 9:55 to 11:00am. APL-9796 is a first-in-class, anti-ZIP12 monoclonal antibody being developed as a disease-modifying therapeutic for pulmonary hypertension.